APO-PERINDOPRIL-INDAPAMIDE 4 MG
PERINDOPRIL ERBUMINE : 4 MG INDAPAMIDE : 1.25 MG · DIN 02297574 · APOTEX INC
Health Canada status: MARKETED
What is APO-PERINDOPRIL-INDAPAMIDE?
APO-PERINDOPRIL-INDAPAMIDE 4 MG contains PERINDOPRIL ERBUMINE : 4 MG INDAPAMIDE : 1.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02297574, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Feb-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-PERINDOPRIL-INDAPAMIDE used for?
Initial treatment of mild to moderate essential hypertension (2mg/0.625mg). Treatment of mild to moderate essential hypertension where combination therapy is appropriate (4mg/1.25mg, 8mg/2.5mg).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02297574 |
|---|---|
| Brand name | APO-PERINDOPRIL-INDAPAMIDE |
| Generic / active ingredient | PERINDOPRIL ERBUMINE : 4 MG INDAPAMIDE : 1.25 MG |
| Manufacturer | APOTEX INC |
| Strength | 4 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09BA04 PERINDOPRIL AND DIURETICS |
| AHFS class | 40:28.24 ; 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Feb-2021 |
| Original market date | 2021-02-02 00:00:00 |
How is it administered?
Once daily, preferably in the morning before a meal. Initial therapy with 2mg/0.625mg. 4mg/1.25mg and 8mg/2.5mg are for maintenance after titration of individual components.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (standard section 11 was listed in TOC but text ends at section 7).
How is it supplied?
Perforated blister packs of 30 tablets; bottles of 100 tablets (for 4 mg / 1.25 mg and 8 mg / 2.5 mg strengths).
Contraindications
Hypersensitivity to drug or sulfonamides; history of ACEI-related angioedema; pregnancy/nursing; severe renal impairment (GFR <30); hypokalemia; severe hepatic impairment; hepatic encephalopathy.
Warnings and precautions
Serious Warning: Fetal injury/death in pregnancy. Risk of life-threatening angioedema, hypotension, neutropenia/agranulocytosis, and choroidal effusion/glaucoma.
Is PERINDOPRIL AND DIURETICS in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09BA04 PERINDOPRIL AND DIURETICS. 25 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-PERINDOPRIL / INDAPAMIDE | 0.625 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02447991 |
| AG-PERINDOPRIL / INDAPAMIDE | 1.25 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02448009 |
| AG-PERINDOPRIL / INDAPAMIDE | 2.5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02448017 |
| APO-PERINDOPRIL-INDAPAMIDE | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02453061 |
| COVERSYL PLUS | 1.25 MG | TABLET | SERVIER CANADA INC | MARKETED | DIN 02246569 |
| COVERSYL PLUS HD | 2.5 MG | TABLET | SERVIER CANADA INC | MARKETED | DIN 02321653 |
| COVERSYL PLUS LD | 0.625 MG | TABLET | SERVIER CANADA INC | MARKETED | DIN 02246568 |
| JAMP PERINDOPRIL/INDAPAMIDE | 0.625 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02554119 |
| JAMP PERINDOPRIL/INDAPAMIDE | 2.5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02554135 |
| JAMP PERINDOPRIL/INDAPAMIDE | 4 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02554127 |
Who else supplies PERINDOPRIL AND DIURETICS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PERINDOPRIL AND DIURETICS appears in 603 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.